Nerve growth factor and bromocriptine: A sequential therapy for human bromocriptine-resistant prolactinomas

C. Missale, M. Losa, F. Boroni, M. Giovanelli, A. Balsari, P. F. Spano

Research output: Contribution to journalArticle

Abstract

Nerve growth factor (NGF) administration to athymic mice with transplanted human bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma prolactin and tumour regression. Sequential administration of NGF and bromocriptine thus may be a promising therapy for patients refractory to bromocriptine.

Original languageEnglish
Pages (from-to)1397-1399
Number of pages3
JournalBritish Journal of Cancer
Volume72
Issue number6
Publication statusPublished - 1995

Keywords

  • D-2 receptors
  • Dopamine
  • Nerve growth factor
  • Pituitary tumours
  • Prolactin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Nerve growth factor and bromocriptine: A sequential therapy for human bromocriptine-resistant prolactinomas'. Together they form a unique fingerprint.

  • Cite this

    Missale, C., Losa, M., Boroni, F., Giovanelli, M., Balsari, A., & Spano, P. F. (1995). Nerve growth factor and bromocriptine: A sequential therapy for human bromocriptine-resistant prolactinomas. British Journal of Cancer, 72(6), 1397-1399.